Novartis | NVS - Assets


Novartis reported $107.29B in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Amgen USD 90.59B 445M Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Bausch Health Companies USD 26.37B 458M Dec/2025
Biogen USD 29.44B 232M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Canopy Growth CAD 1.07B 165.17M Sep/2025
Corcept Therapeutics USD 823.61M 21.88M Sep/2025
Drreddys Laboratories INR 6.26B 161.9M Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Glaxosmithkline GBP 82.45B 23.19B Sep/2025
J&J USD 199.21B 6.39B Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Pacira USD 1.3B 239.68M Sep/2025
Perrigo USD 10.08B 10.1M Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Phibro Animal Health USD 1.41B 20.03M Dec/2025
Prestige Brands USD 3.49B 52.46M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sanofi EUR 126.81B 2.99B Dec/2025
Sanofi EUR 126.81B 25.48B Dec/2025
Supernus Pharmaceuticals USD 1.42B 37.35M Sep/2025
Zoetis USD 15.47B 308M Dec/2025